A severe gut disease in premature infants, known as necrotizing enterocolitis (NEC), does far more than damage the intestines—it fundamentally alters brain development, leaving up to 40% of survivors with lasting cognitive, motor, and behavioral impairments. A comprehensive new review reveals that the risk of neurodevelopmental impairment (NDI) in these babies extends well beyond the known vulnerabilities of prematurity. The study synthesizes decades of clinical data and emerging molecular evidence to show that NEC itself drives brain injury through a powerful inflammatory cascade originating in the gut, highlighting an urgent need for targeted therapies.
NEC is one of the most common and lethal gastrointestinal emergencies in preterm infants, with mortality rates ranging from 15% to 30%. While advances in neonatal intensive care have improved survival, the long-term neurological consequences have become increasingly apparent. Survivors face a significantly higher risk of cerebral palsy, vision and hearing loss, and cognitive delays compared to their premature peers without NEC. Historically, these deficits were often attributed solely to the fragility of the premature brain. However, mounting evidence points to a more direct link: the severe systemic inflammation triggered by a necrotic bowel appears to inflict specific, preventable damage to the developing brain. Based on these challenges, there is an urgent need to conduct in-depth research into the distinct mechanisms by which NEC impacts the neonatal brain to develop effective preventative and therapeutic strategies.
A research team led by Augusto Zani, along with colleagues Michele Bosisio and Miguel A. Garcia, from the Division of Surgery at Washington University in St Louis in Missouri, USA, published (DOI: 10.1136/wjps-2026-001199) their comprehensive analysis in the World Journal of Pediatric Surgery on July 13, 2026. The review synthesizes findings from clinical outcome studies, neuroimaging, and preclinical models to map out how NEC leads to NDI and to identify promising new avenues for intervention.
The review highlights that the severity of the intestinal disease is a primary driver of brain injury. Surgically treated infants, who have more extensive bowel necrosis, consistently show higher rates of cerebral palsy, lower IQ scores, and greater cognitive deficits than those managed medically. Neuroimaging studies confirm this link, revealing that infants with NEC have reduced brain volume, delayed cortical folding, and significant white matter injury (WMI) that correlates with the degree of intestinal inflammation. This brain damage appears to be mediated by a breakdown of the blood-brain barrier, allowing gut-derived immune cells and inflammatory proteins to infiltrate the brain. Specifically, the review points to high-mobility group box 1 (HMGB1), a protein released from dying gut cells, as a critical driver of this process. Preclinical studies show that blocking HMGB1-Toll-like receptor 4 (TLR4) signaling or preventing the infiltration of immune cells into the brain can reduce injury in animal models. The review also highlights emerging risk factors like hyponatremia and thrombocytopenia as potential early warning signs for NDI, underscoring the importance of rapid surgical intervention to remove necrotic tissue.
The review emphasizes that the severity of bowel damage in NEC directly determines the degree of brain injury. It notes that brain problems were previously attributed largely to prematurity, but the findings indicate that the gut actively contributes to brain injury through inflammation. Importantly, this inflammation-driven process may be treatable, and specific molecular pathways such as the HMGB1–TLR4 axis are promising targets. The authors hope that future research will translate these biological insights into real-world therapies that protect the brains of these fragile infants and improve their quality of life for decades to come.
This research provides a roadmap for clinical practice and future trials. It reinforces the need for structured, long-term neurodevelopmental follow-up for all NEC survivors, beginning in the neonatal period and extending into school age, to enable early intervention. It suggests that clinical decisions, such as the timing of surgery, have profound neurological implications and advocates for early laparotomy to limit the inflammatory burden. The mechanistic findings open the door for testing novel therapies in clinical trials, such as antioxidants like N-acetylcysteine, human milk oligosaccharides, or HMGB1 inhibitors like glycyrrhizin, which have shown promise in preclinical models. Ultimately, the study shifts the paradigm from simply treating the gut to protecting the brain, paving the way for a dual-pronged clinical approach that aims to save both the intestines and the mind.
